Skip to main content
SpringerLink
Log in

Cholinesterases: New Roles in Brain Function and in Alzheimer's Disease

  • Published:
Neurochemical Research Aims and scope Submit manuscript

Abstract

The most important therapeutic effect of cholinesterase inhibitors (ChEI) on approximately 50% of Alzheimer's disease (AD) patients is to stabilize cognitive function at a steady level during a 1-year period of treatment as compared to placebo. Recent studies show that in a certain percentage (approximately 20%) of patients this cognitive stabilizing effect can be prolonged up to 24 months. This long-lasting effect suggests a mechanism of action other than symptomatic and cholinergic. In vitro and in vivo studies have consistently demonstrated a link between cholinergic activation and APP metabolism. Lesions of cholinergic nuclei cause a rapid increase in cortical APP and CSF. The effect of such lesions can be reversed by ChEI treatment. Reduction in cholinergic neurotransmission–experimental or pathological, such as in AD–leads to amyloidogenic metabolism and contributes to the neuropathology and cognitive dysfunction. To explain the long-term effect of ChEI, mechanisms based on β-amyloid metabolism are postulated. Recent data show that this mechanism may not necessarily be related to cholinesterase inhibition. A second important aspect of brain cholinesterase function is related to enzymatic differences. The brain of mammals contains two major forms of cholinesterases: acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). The two forms differ genetically, structurally, and for their kinetics. Butyrylcholine is not a physiological substrate in mammalian brain, which makes the function of BuChE of difficult interpretation. In human brain, BuChE is found in neurons and glial cells, as well as in neuritic plaques and tangles in AD patients. Whereas, AChE activity decreases progressively in the brain of AD patients, BuChE activity shows some increase. To study the function of BuChE, we perfused intracortically the rat brain with a selective BuChE inhibitor and found that extracellular acetylcholine increased 15-fold from 5 nM to 75 nM concentrations with little cholinergic side effect in the animal. Based on these data and on clinical data showing a relation between cerebrospinal fluid (CSF) BuChE inhibition and cognitive function in AD patients, we postulated that two pools of cholinesterases may be present in brain, the first mainly neuronal and AChE dependent and the second mainly glial and BuChE dependent. The two pools show different kinetic properties with regard to regulation of ACh concentration in brain and can be separated with selective inhibitors. Within particular conditions, such as in mice nullizygote for AChE or in AD patients at advanced stages of the disease, BuChE may replace AChE in hydrolizing brain acetylcholine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

REFERENCES

  1. Farlow, M. 2000. New approaches in assessing delay of progression of AD. Symp. Pivotal Res. World Alzheimer Congress, Washington, D. C. Abstr:10–11.

  2. Anand, R., Hartman, R., and Messina, J. 1998. Long-term treatment with rivastigmine continue to provide benefits for up to one year. Fifth International Geneva/Springfield Symposium on Advances in Alzheimer Therapy Geneva, Abstr.:18.

  3. Nitsch, R. M. 1992. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258:304–307.

    PubMed  Google Scholar 

  4. Mori, F., Lai, C. C., Fusi, F., and Giacobini, E. 1995. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neurol. Rep. 6:633–636.

    Google Scholar 

  5. Racchi, M., Schmidt, B., and Koenig, G. 1999. Treatment with metrifonate promotes soluble amyloid precursor protein release from SH-SY5Y neuroblastoma cells. Alz. Dis. Assoc. Dis 27: 679–688.

    Google Scholar 

  6. Pakaski, M., Rakonczay, Z., and Kasa, P. 2001. Reversible or irreversible cholinesterase inhibitors cause changes in neuronal amyloid percursor processing and protein kinase C level in vitro. Neurochem. Int. 38:219–226.

    PubMed  Google Scholar 

  7. Giacobini, E. 1996. Cholinesterase inhibitors do more than inhibit cholinesterase. Pages 187–204, in Becker, R. and Giacobini, E. (eds.), Alzheimer Disease: From Molecular Biology to Therapy, Birkhäuser, Boston.

    Google Scholar 

  8. Nitsch, R. 2000. Muscarinic agonists reduce CSF levels of amy-loid beta-peptides in patients with Alzheimer's disease. XVth International Symposium of Medicinal Chemistry, Bologna, Abstr M1-41:52.

  9. Lahiri, D. K., Farlow, M. R., Hintz, N., Utsuki, T., and Greig, N. H. 2000. Cholinesterase inhibitors, β-amyloid precursor protein and amyloid 3-peptides in Alzheimer's disease. Acta Neurol. Scand. (Suppl.) 176:60–67.

    Google Scholar 

  10. Svensson, A. L. and Giacobini, E. 2000. Cholinesterase inhibitors do more than inhibit cholinesterase. Pages 227–235, in Giacobini, E. (ed.), Cholinesterases and Cholinesterase Inhibitors, Martin Dunitz.

  11. Shaw, K., Utsuki, T., Rogers, J., Qiang-Sheng, Y., Samba-murti, K., and Brossi, A. 2001. Phenserine regulates translation of β-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc. Natl. Acad. Sci. USA. 19:7605–7610.

    Google Scholar 

  12. Lahiri, D. K., Farlow, M. R., Ge, Y. W., Sambamurti, K., Utsuki, T., Ingram, D. K., and Greig, N. H. 2002. Phenserine: A new generation of cholinesterase inhibitors with amyloid-modifying properties. Seventh International Geneva Spring-field Symposium 2002. Abstr.:80.

  13. Inestrosa, N. C., Alvarez, A., Reyes, A., and De Ferrari, G. V. 2000. Acetylcholinesterase-amyloid-peptide interaction and Wnt signaling involvment in A-beta neurotoxicity. Acta Neurol. Scand. (Suppl.) 176:53–59.

    Google Scholar 

  14. Inestrosa, N. C. and De Ferrari, G. V. Cholinesterase inhibitors with anti-amyloid properties. 7th International Geneva Springfield Symposium 2002. Abstr.:74.

  15. Geula, C. and Mesulam, M. 1989. Special properties of cholinesterases in the cerebral cortex of Alzheimer's disease. Brain Res. 498:185–189.

    PubMed  Google Scholar 

  16. Alvarez, A. 1997. Acetylcholinesterase promotes the aggregation of amyloid ∃-peptide fragments by forming a complex with the growing fibrils. J. Mol. Biol. 272:348–361.

    PubMed  Google Scholar 

  17. De Ferrari, G. V., Canales, M. A., Shin, I., Weiner, L. M., Silman, I., and Inestrosa, N. C. 2001. A structural motif of acetylcholinesterase that promotes amyloid ∃-peptide fibril formation. Biochemistry 40:10447–10457.

    PubMed  Google Scholar 

  18. Giacobini, E. 2000. Cholinesterase inhibitors: From the calabar bean to Alzheimer therapy. Pages 181–122, in Giacobini, E. (ed.), Cholinesterase and Cholinesterase Inhibitors: From Molecular Biology to Therapy, Martin Dunitz, London.

    Google Scholar 

  19. Saez-Valero, J., Sberna, G., McLean, C. A., and Small, D. H. 1999. Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer's disease. J. Neurochem. 72:1600–1608.

    PubMed  Google Scholar 

  20. Small, D. H., Sberna, G., and Li, Q. X. 1998. The ∃-amyloid protein influence acetylcholinesterase expression, assembly and glycosylation. Sixth International Conference on Alzheimer's Disease and Related Disorders, Amsterdam. Abstr.:880.S.209.

  21. Inestrosa, N., Alvarez, A., and Perez, C. A. 1996. Acetylcholinesterase accelerates assembly of amyloid-∃-peptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme. Neuron 16:881–891.

    PubMed  Google Scholar 

  22. Rees, T., Hammond, P., Younkin, S., Soreq, H., and Brimijoin, S., 2002. Acetyl-cholinesterase facilitates amyloid deposition in a mouse model of Alzheimer's disease. Seventh International Symposium Cholinergic Mechanisms, St. Moritz Abstr.:13.

  23. Sberna, G., Saez-Valero, J., and Li, Q. X. 1998. Acetyl-cholinesterase is increased in the brains of transgenic mice expressing C-terminal fragment of the ∃-amyloid protein precursor of Alzheimer's disease. J. Neurochem. 71:723–731.

    PubMed  Google Scholar 

  24. Haroutunian, V., Wallace, W. C., and Greig, N. 2000. Induction, secretion and pharmacological regulation of beta-APP in animal model systems. Sixth International Stockholm/Springfield Symposium Advances in Alzheimer Therapy. Abstr.:81.

  25. Suh, Y. H., Chong, Y. H., and Kim, S. H. 1996. Molecular physiology, biochemistry and pharmacology of Alzheimer's amyloid precursor protein (APP). Ann. N. Y. Acad. Sci. 786:169–183.

    PubMed  Google Scholar 

  26. Wallace, W. C., Bragin, V., and Robakis, N. K. 1991. Increased byosynthesis of Alzheimer amyloid precursor protein in the cerebral cortex of rats with lesions of the nucleus basalis Meynert. Mol. Brain Res. 10:173–178.

    PubMed  Google Scholar 

  27. Bernhardt, T. and Woelk, H. 2000. Metrifronate demonstrates sustained improvement in cognition and global functioning in a 12-month, double-blind placebo-controlled trial. Europ. Neurol. Soc. Meet. (Jerusalem), p. 36.

  28. Winblad, B., Engedal, K., and Soininen, H. 1999. Donepezil enhances global function, cognition and activities of daily living compared with placebo one year. Twelfth Congretional ECNP, London. Abstr.:30.

  29. Raskind, M. A., Peskind, E. R., and Wessel, T. 2000. Galanta-mine in AD: A sixth month randomized, placebo-controlled trial with a 6-month extension. Neurology 54:2261–2268.

    PubMed  Google Scholar 

  30. Silver, A. 1974. The biology of cholinesterases. Elsev. Publ USA, Agricultural Res. Council Institute: 426–447.

    Google Scholar 

  31. Giacobini, E. 2001. Selective inhibitors of butyrylcholinesterase: A valid alternative for therapy of Alzheimer's disease? Drug Aging 18:891–898.

    Google Scholar 

  32. Wright, C. I, Geula, C., and Mesulam, M. M. 1993. Neuroglial cholinesterases in the normal brain and in Alzheimer's disease: Relationship to plaques, tangles and patterns of selective vulnerability. Ann. Neurol. 34:373–384.

    PubMed  Google Scholar 

  33. Perry, E. K., Perry, R. H., Blessed G., and Tomlinson, B. E. 1978. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol. Appl. Neurobiol. 4:273–277.

    PubMed  Google Scholar 

  34. Cuadra, G., Summers, K., and Giacobini, E. 1994. Cholinesterase inhibitor effects on neurotransmitters in rat cortex in vivo. J. Pharmacol. Exper. Ther. 270:277–284.

    Google Scholar 

  35. Giacobini, E., Griffini, P. L., Maggi T., et al. 1996. The effect of MF8622, a selective butyrylcholinesterase inhibitor on cortical levels of acetylcholine. Soc. Neurosci. 22:203.

    Google Scholar 

  36. Cuadra, G. and Giacobini E. 1995. Coadministration of cholinesterase inhibitors and idazoxan: Effects of neurotransmitters in rat cortex in vivo. J. Pharm. Exp. Ther. 273:230–240.

    Google Scholar 

  37. Greig, N. H., Utsuki, T., Yu, Q., et al. 2001. Butyryl-cholinesterase: A new therapeutic target in AD treatment? Alz. Insights 7,2, 1–4.

    Google Scholar 

  38. Mesulam, M. M., Guillozet, A., Shaw, P., Levey, A., Duysen, E. G., and Lockridge, O. 2002. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyl-cholinesterase to hydrolyse acetylocholine. Neuroscience 110: 627–639.

    PubMed  Google Scholar 

  39. Mesulam, M. M. and Geula, C. 1994. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann. Neurol. 36:722–727.

    PubMed  Google Scholar 

  40. Darvesh, S., MacKnight, C., and Rockwood, K. 2001. Butyryl-cholinesterase and cognitive function. Int. Psychogeriatr. 13: 461–464.

    PubMed  Google Scholar 

  41. Costa, J., Anand, R., Cutler, N., et al. 1999. Correlation between cognitive effects and level of acetylcholinesterase inhibition in a trial of rivastigmine in Alzheimer's patients. Proc. Am. Psych. Assoc. Poster NR:561.

  42. Giacobini, E., et al. 2002. Acetyl-and butyrylcholinesterase inhibition by rivastigmine in cerebrospinal fluid of patients with Alzheimer's disease correlates with cognitive benefit. J. Neural Transm. In press.

Download references

Author information

Authors and Affiliations

  1. Department of Geriatrics, University of Geneva, Medical school, University Hospitals of Geneva, CH-1226, Thônex, Geneva, Switzerland

    Ezio Giacobini

Authors
  1. Ezio Giacobini
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giacobini, E. Cholinesterases: New Roles in Brain Function and in Alzheimer's Disease. Neurochem Res 28, 515–522 (2003). https://doi.org/10.1023/A:1022869222652

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1022869222652

Search

Navigation